The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study
Open accessAbstract
BACKGROUND: Activation of the mitogen-activated protein kinase pathway is important for growth of pediatric low-grade gliomas (LGGs). The aim of this study was to determine the recommended phase II dose (RP2D) and the dose-limiting toxicities (DLTs) of the MEK inhibitor selumetinib in children with progressive LGG. METHODS: Selumetinib was administered orally starting at 33 mg/m2/dose b.i.d., using the modified continual reassessment method. Pharmacokinetic analysis was performed during the first course. BRAF aberrations in tumor tissue were determined by real-time polymerase chain reaction and fluorescence in situ hybridization. RESULTS: Thirty-eight eligible subjects were enrolled. Dose levels 1 and 2 (33 and 43 mg/m2/dose b.i.d.) were excessively toxic. DLTs included grade 3 elevated amylase/lipase (n = 1), headache (n = 1), mucositis (n = 2), and grades 2-3 rash (n = 6). At dose level 0 (25 mg/m2/dose b.i.d, the RP2D), only 3 of 24 subjects experienced DLTs (elevated amylase/lipase, rash, and mucositis). At the R2PD, the median (range) area under the curve (AUC0-∞) and apparent oral clearance of selumetinib were 3855 ng*h/mL (1780 to 7250 ng × h/mL) and 6.5 L × h-1 × m-2 (3.4 to 14.0 L × h-1 × m-2), respectively. Thirteen of 19 tumors had BRAF abnormalities. Among the 5 (20%) of 25 subjects with sustained partial responses, all at the RP2D, 4 had BRAF aberrations, 1 had insufficient tissue. Subjects received a median of 13 cycles (range: 1-26). Fourteen (37%) completed all protocol treatment (26 cycles [n = 13], 13 cycles [n = 1]) with at least stable disease; 2-year progression-free survival at the RP2D was 69 ± SE 9.8%. CONCLUSION: Selumetinib has promising antitumor activity in children with LGG. Rash and mucositis were the most common DLTs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ostrom, Q. T., Gittleman, H., Farah, P., Ondracek, A., Chen, Y., Wolinsky, Y., Stroup, N. E., Kruchko, C., & Barnholtz-Sloan, J. S. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not151 · Cited by 11,994
Dolecek, T. A., Propp, J. M., Stroup, N. E., & Kruchko, C. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos218 · Cited by 1,710
Schindler, G., Capper, D., Meyer, J., Janzarik, W., Omran, H., Herold-Mende, C., Schmieder, K., Wesseling, P., Mawrin, C., Hasselblatt, M., et al. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0802-6 · Cited by 1,034
Jones, D. T. W., Kocialkowski, S., Liu, L., Pearson, D. M., Bäcklund, L. M., Ichimura, K., & Collins, V. P. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-2097 · Cited by 944
Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas
the St. Jude Children's Research Hospital–Washington University Pediatric Cancer Genome Project (2013) · Nature Genetics · doi:10.1038/ng.2611 · Cited by 835
Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma
the International Cancer Genome Consortium PedBrain Tumor Project, Jones, D. T. W., Hutter, B., Jäger, N., Korshunov, A., Kool, M., Warnatz, H.-J., Zichner, T., Lambert, S. R., Ryzhova, M., et al. (2013) · Nature Genetics · doi:10.1038/ng.2682 · Cited by 825
Yeh, T. C., Marsh, V., Bernat, B. A., Ballard, J., Colwell, H., Evans, R. J., Parry, J., Smith, D., Brandhuber, B. J., Gross, S., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1150 · Cited by 578
Adjei, A. A., Cohen, R. B., Franklin, W., Morris, C., Wilson, D., Molina, J. R., Hanson, L. J., Gore, L., Chow, L., Leong, S., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.4956 · Cited by 570
Carvajal, R. D., Sosman, J. A., Quevedo, J. F., Milhem, M. M., Joshua, A. M., Kudchadkar, R. R., Linette, G. P., Gajewski, T. F., Lutzky, J., Lawson, D. H., et al. (2014) · JAMA · doi:10.1001/jama.2014.6096 · Cited by 433
Ater, J. L., Zhou, T., Holmes, E., Mazewski, C. M., Booth, T. N., Freyer, D. R., Lazarus, K. H., Packer, R. J., Prados, M., Sposto, R., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.6054 · Cited by 433
Self-citationFarley, J., Brady, W. E., Vathipadiekal, V., Lankes, H. A., Coleman, R., Morgan, M. A., Mannel, R., Yamada, S. D., Mutch, D., Rodgers, W. H., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70572-7 · Cited by 413
Bandopadhayay, P., Bergthold, G., London, W. B., Goumnerova, L. C., Morales La Madrid, A., Marcus, K. J., Guo, D., Ullrich, N. J., Robison, N. J., Chi, S. N., et al. (2014) · Pediatric Blood & Cancer · doi:10.1002/pbc.24958 · Cited by 313
Forshew, T., Tatevossian, R. G., Lawson, A. R., Ma, J., Neale, G., Ogunkolade, B. W., Jones, T. A., Aarum, J., Dalton, J., Bailey, S., et al. (2009) · The Journal of Pathology · doi:10.1002/path.2558 · Cited by 304
Sievert, A. J., Lang, S.-S., Boucher, K. L., Madsen, P. J., Slaunwhite, E., Choudhari, N., Kellet, M., Storm, P. B., & Resnick, A. C. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1219232110 · Cited by 285
Kirkwood, J. M., Bastholt, L., Robert, C., Sosman, J., Larkin, J., Hersey, P., Middleton, M., Cantarini, M., Zazulina, V., Kemsley, K., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1491 · Cited by 278
Phase II Study of Weekly Vinblastine in Recurrent or Refractory Pediatric Low-Grade Glioma
Bouffet, E., Jakacki, R., Goldman, S., Hargrave, D., Hawkins, C., Shroff, M., Hukin, J., Bartels, U., Foreman, N., Kellie, S., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.34.5843 · Cited by 233
Self-citationPhase II study of sorafenib in children with recurrent or progressive low-grade astrocytomas
Karajannis, M. A., Legault, G., Fisher, M. J., Milla, S. S., Cohen, K. J., Wisoff, J. H., Harter, D. H., Goldberg, J. D., Hochman, T., Merkelson, A., et al. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou059 · Cited by 223
Banerji, U., Camidge, D. R., Verheul, H. M. W., Agarwal, R., Sarker, D., Kaye, S. B., Desar, I. M. E., Timmer-Bonte, J. N. H., Eckhardt, S. G., Lewis, K. D., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2483 · Cited by 211
Greenberger, B. A., Pulsifer, M. B., Ebb, D. H., MacDonald, S. M., Jones, R. M., Butler, W. E., Huang, M. S., Marcus, K. J., Oberg, J. A., Tarbell, N. J., et al. (2014) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2014.04.053 · Cited by 196
Nicholson, H. S., Kretschmar, C. S., Krailo, M., Bernstein, M., Kadota, R., Fort, D., Friedman, H., Harris, M. B., Tedeschi‐Blok, N., Mazewski, C., et al. (2007) · Cancer · doi:10.1002/cncr.22961 · Cited by 196
Robert, C., Dummer, R., Gutzmer, R., Lorigan, P., Kim, K. B., Nyakas, M., Arance, A., Liszkay, G., Schadendorf, D., Cantarini, M., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70237-7 · Cited by 169
Gururangan, S., Fangusaro, J., Poussaint, T. Y., McLendon, R. E., Onar-Thomas, A., Wu, S., Packer, R. J., Banerjee, A., Gilbertson, R. J., Fahey, F., et al. (2014) · Neuro-Oncology · doi:10.1093/neuonc/not154 · Cited by 163
Self-citationSodhi, A., Montaner, S., Miyazaki, H., & Gutkind, J. S. (2001) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2001.5532 · Cited by 161
Catalanotti, F., Solit, D. B., Pulitzer, M. P., Berger, M. F., Scott, S. N., Iyriboz, T. A., Lacouture, M. E., Panageas, K. S., Wolchok, J. D., Carvajal, R. D., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3476 · Cited by 141
Adaptive Dose-Finding Studies: A Review of Model-Guided Phase I Clinical Trials
Iasonos, A. E., & O’Quigley, J. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.6051 · Cited by 119
Ciuffreda, L., Bufalo, D. D., Desideri, M., Sanza, C. D., Stoppacciaro, A., Ricciardi, M. R., Chiaretti, S., Tavolaro, S., Benassi, B., Bellacosa, A., et al. (2009) · Neoplasia · doi:10.1593/neo.09398 · Cited by 111
Initial testing (stage 1) of AZD6244 (ARRY‐142886) by the pediatric preclinical testing program
Kolb, E. A., Gorlick, R. G., Houghton, P. J., Morton, C. L., Neale, G. A. M., Keir, S. T., Carol, H., Lock, R. B., Phelps, D. A., Kang, M. H., et al. (2010) · Pediatric Blood & Cancer · doi:10.1002/pbc.22576 · Cited by 110
Ris, M. D., Beebe, D. W., Armstrong, F. D., Fontanesi, J., Holmes, E., Sanford, R. A., & Wisoff, J. H. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.1371 · Cited by 96
The molecular and cell biology of pediatric low-grade gliomas
Chen, Y.-H., & Gutmann, D. H. (2013) · Oncogene · doi:10.1038/onc.2013.148 · Cited by 82
Sie, M., de Bont, E. S. J. M., Scherpen, F. J. G., Hoving, E. W., & den Dunnen, W. F. A. (2010) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2010.01113.x · Cited by 53
Onar, A., Koçak, M., & Boyett, J. M. (2009) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543400902800486 · Cited by 48
Self-citationHöchster, H. S., Uboha, N. V., Messersmith, W. A., Gold, P. J., O’Neil, B. H., Cohen, D. J., Denlinger, C. S., Cohen, S., Leichman, C. G., & Leichman, L. (2014) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2609-3 · Cited by 39
Late causes of death in children treated for CNS malignancies
Perkins, S. M., Fei, W., Mitra, N., & Shinohara, E. T. (2013) · Journal of Neuro-Oncology · doi:10.1007/s11060-013-1197-0 · Cited by 39
Gao, J., Wang, C., Tong, H., Wen, S., Huang, Z., & Tang, C. (2015) · Scientific Reports · doi:10.1038/srep16382 · Cited by 26
Tacke, U., Karger, D., Spreer, J., Berlis, A., Nikkhah, G., & Korinthenberg, R. (2011) · Child s Nervous System · doi:10.1007/s00381-010-1370-0 · Cited by 10
Price (1999) · doi:10.1002/1531-8249(199903)45:3
Cited by
Selumetinib in Children with Inoperable Plexiform Neurofibromas
Gross, A. M., Wolters, P. L., Dombi, E., Baldwin, A., Whitcomb, P., Fisher, M. J., Weiss, B., Kim, A., Bornhorst, M., Shah, A. C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1912735 · Cited by 726
Self-citationGlioma targeted therapy: insight into future of molecular approaches
Yang, K., Wu, Z., Zhang, H., Zhang, N., Wu, W., Wang, Z., Dai, Z., Zhang, X., Zhang, L., Peng, Y., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01513-z · Cited by 704
Fangusaro, J., Onar-Thomas, A., Young Poussaint, T., Wu, S., Ligon, A. H., Lindeman, N., Banerjee, A., Packer, R. J., Kilburn, L. B., Goldman, S., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30277-3 · Cited by 507
Self-citationIntegrated Molecular and Clinical Analysis of 1,000 Pediatric Low-Grade Gliomas
Ryall, S., Zapotocky, M., Fukuoka, K., Nobre, L., Guerreiro Stucklin, A., Bennett, J., Siddaway, R., Li, C., Pajovic, S., Arnoldo, A., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.011 · Cited by 474
Self-citationAlterations in ALK/ROS1/NTRK/MET drive a group of infantile hemispheric gliomas
Guerreiro Stucklin, A. S., Ryall, S., Fukuoka, K., Zapotocky, M., Lassaletta, A., Li, C., Bridge, T., Kim, B., Arnoldo, A., Kowalski, P. E., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12187-5 · Cited by 367
Metadata
- Authors
- Banerjee, A., Jakacki, R. I., Onar-Thomas, A., Wu, S., Nicolaides, T., Young Poussaint, T., Fangusaro, J., Phillips, J., Perry, A., Turner, D., Prados, M., Packer, R. J., Qaddoumi, I., Gururangan, S., Pollack, I. F., Goldman, S., Doyle, L. A., Stewart, C. F., Boyett, J. M., Kun, L. E., & Fouladi, M.
- Venue
- Neuro-Oncology
- Publisher
- Oxford University Press (OUP)
- Published
- 2017-02-28
- Volume
- 19
- Issue
- 8
- Pages
- 1135-1144
- ISSN
- 1522-8517 (ISSN-L)
- 1523-5866
- OpenAlex
- W2591910005
- Cited by
- 319
- References
- 36
- FWCI
- 17.13
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.